Table 1.
Baseline, Operative, and Postoperative Characteristics of the 260 Study Subjects Stratified by UTXB2 and the 39 Excluded Subjects
| Characteristic | <400 pg/mg Creatinine | ≥400 pg/mg Creatinine | P Value | Total Included | Total Excluded | P Value |
|---|---|---|---|---|---|---|
| No. of patients | 178 | 82 | 260 | 39 | ||
| Age, y | 63 (55–69) | 66 (57–73) | 0.07 | 63 (56–71) | 63 (59–72) | 0.44 |
| Male sex | 153 (86%) | 58 (71%) | 0.006 | 211 (81%) | 25 (64%) | 0.02 |
| White race | 17 (10%) | 18 (22%) | 0.01 | 35 (13%) | 5 (13%) | 1.0 |
| Body mass index, kg/m2 | 29 (26–33) | 28 (26–33) | 0.87 | 29 (26–33) | 26 (24–30) | <0.001 |
| Medical history, n | ||||||
| Hypertension | 148 (83%) | 65 (79%) | 0.49 | 213 (82%) | 32 (84%) | 0.82 |
| Dyslipidemia | 150 (85%) | 65 (79%) | 0.29 | 215 (83%) | 34 (89%) | 0.48 |
| Diabetes | 56 (32%) | 39 (48%) | 0.018 | 95 (37%) | 11 (29%) | 0.47 |
| Heart failure | 16 (9%) | 18 (22%) | 0.006 | 34 (13%) | 4 (10%) | 0.80 |
| Peripheral/cerebrovascular disease | 28 (16%) | 18 (22%) | 0.226 | 46 (18%) | 8 (21%) | 0.66 |
| Atrial fibrillation | 5 (3%) | 3 (4%) | 0.71 | 8 (3%) | 4 (10%) | 0.06 |
| Current tobacco use | 33 (19%) | 27 (33%) | 0.017 | 60 (23%) | 11 (28%) | 0.55 |
| Myocardial infarction | 64 (36%) | 39 (48%) | 0.08 | 103 (40%) | 18 (46%) | 0.49 |
| Prior PCI | 40 (22%) | 12 (15%) | 0.18 | 52 (20%) | 9 (23%) | 0.67 |
| Preoperative LVEF | 0.78 | 0.75 | ||||
| ≤30% | 14 (8%) | 8 (10%) | 22 (8%) | 3 (8%) | ||
| 30–50% | 59 (33%) | 29 (35%) | 88 (34%) | 11 (28%) | ||
| >50% | 105 (59%) | 45 (55%) | 150 (58%) | 25 (64%) | ||
| Urgent/emergent surgery | 100 (56%) | 57 (70%) | 0.06 | 157 (60%) | 30 (77%) | 0.052 |
| Euroscore | 3 (1–5) | 4 (3–6) | 0.004 | 3 (2–5) | 4 (2–5) | 0.25 |
| Arterial graft implanted | 175 (98%) | 79 (96%) | 0.38 | 254 (98%) | 36 (92%) | 0.10 |
| No. of SVGs per subject | 0.2 | 0.03 | ||||
| 1 | 48 (27%) | 20 (24%) | 68 (26%) | 17 (44%) | ||
| 2 | 70 (39%) | 41 (50%) | 111 (43%) | 12 (31%) | ||
| 3 | 44 (25%) | 12 (15%) | 56 (22%) | 10 (26%) | ||
| ≥4 | 16 (9%) | 9 (11%) | 25 (10%) | 0 (0%) | ||
| Medications at the time of SVG patency assessment | ||||||
| Aspirin | 178 (100%) | 82 (100%) | 1.0 | 260 (100%) | 37 (95%) | <0.001 |
| Nonaspirin antiplatelet | 0 (0%) | 0 (0%) | 1.0 | 0 (0%) | 33 (85%) | <0.001 |
| Aspirin low dose (<325 mg) | 11 (6%) | 10 (12%) | 0.14 | 21 (8%) | 12 (31%) | <0.001 |
| Oral anticoagulation | 6 (3%) | 7 (9%) | 0.12 | 13 (5%) | 3 (8%) | 0.49 |
| β‐Blocker | 153 (86%) | 61 (75%) | 0.035 | 214 (82%) | 35 (90%) | 0.36 |
| ACE inhibitor/ARB | 113 (63%) | 47 (57%) | 0.4 | 160 (62%) | 26 (67%) | 0.60 |
| Lipid‐lowering agent | 162 (91%) | 65 (79%) | 0.015 | 227 (87%) | 37 (95%) | 0.28 |
Values are median (IQR) or n (%). ACE indicates angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; SVG, saphenous vein graft; UTXB2, urinary thromboxane B2.